This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boyle-Vavra, S.
Right arrow Articles by Daum, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyle-Vavra, S.
Right arrow Articles by Daum, R. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2000, p. 272-277, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Reversion of the Glycopeptide Resistance Phenotype in Staphylococcus aureus Clinical Isolates

Susan Boyle-Vavra,1,* Sarah K. Berke,1 Jean C. Lee,2 and Robert S. Daum1

The University of Chicago Children's Hospital, Department of Pediatrics, Chicago, Illinois 60637,1 and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 021152

Received 1 June 1999/Returned for modification 14 July 1999/Accepted 29 October 1999

The recent identification of glycopeptide intermediate-resistant Staphylococcus aureus (GISA) clinical isolates has provided an opportunity to assess the stability of the glycopeptide resistance phenotype by nonselective serial passage and to evaluate reversion-associated cell surface changes. Three GISA isolates from the United States (MIC of vancomycin = 8 µg/ml) and two from Japan (MICs of vancomycin = 8 and 2 µg/ml) were passaged daily on nutrient agar with or without vancomycin supplementation. After 15 days of passage on nonselective medium, vancomycin- and teicoplanin-susceptible revertants were obtained from each GISA isolate as determined by broth dilution MIC. Revertant isolates were compared with parent isolates for changes in vancomycin heteroresistance, capsule production, hemolysis phenotype, coagulase activity, and lysostaphin susceptibility. Several revertants lost the subpopulations with intermediate vancomycin resistance, whereas two revertants maintained them. Furthermore, although all of the parent GISA isolates produced capsule type 5 (CP5), all but one revertant tested no longer produced CP5. In contrast, passage on medium containing vancomycin yielded isolates that were still intermediately resistant to vancomycin, had no decrease in the MIC of teicoplanin, and produced detectable CP5. No consistent changes in the revertants in hemolysis phenotype, lysostaphin susceptibility, or coagulase activities were discerned. These data indicate that the vancomycin resistance phenotype is unstable in clinical GISA isolates. Reversion of the vancomycin resistance phenotype might explain the difficulty in isolating vancomycin-resistant clinical isolates from the blood of patients who fail vancomycin therapy and, possibly, may account for some of the difficulties in identifying GISA isolates in the clinical laboratory.

* Corresponding author. Mailing address: University of Chicago Children's Hospital, MC 6054, 5841 S. Maryland Ave., Chicago, IL 60637. Phone: (773) 702-6401. Fax: (773) 702-1196. E-mail address: sboyleva{at}midway.uchicago.edu.

Antimicrobial Agents and Chemotherapy, February 2000, p. 272-277, Vol. 44, No. 2
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Musta, A. C., Riederer, K., Shemes, S., Chase, P., Jose, J., Johnson, L. B., Khatib, R. (2009). Vancomycin MIC plus Heteroresistance and Outcome of Methicillin-Resistant Staphylococcus aureus Bacteremia: Trends over 11 Years. J. Clin. Microbiol. 47: 1640-1644 [Abstract] [Full Text]  
  • Kirby, A., Mohandas, K., Broughton, C., Neal, T. J., Smith, G. W., Pai, P., Nistal de Paz, C. (2009). In vivo development of heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA), GISA and daptomycin resistance in a patient with meticillin-resistant S. aureus endocarditis. J Med Microbiol 58: 376-380 [Abstract] [Full Text]  
  • Holmes, R. L., Jorgensen, J. H. (2008). Inhibitory Activities of 11 Antimicrobial Agents and Bactericidal Activities of Vancomycin and Daptomycin against Invasive Methicillin-Resistant Staphylococcus aureus Isolates Obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52: 757-760 [Abstract] [Full Text]  
  • Amiali, N. M., Mulvey, M. R., Berger-Bachi, B., Sedman, J., Simor, A. E., Ismail, A. A. (2008). Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 61: 95-102 [Abstract] [Full Text]  
  • Bogdanovich, T., Clark, C., Kosowska-Shick, K., Dewasse, B., McGhee, P., Appelbaum, P. C. (2007). Antistaphylococcal Activity of CG400549, a New Experimental FabI Inhibitor, Compared with That of Other Agents. Antimicrob. Agents Chemother. 51: 4191-4195 [Abstract] [Full Text]  
  • Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., Tomasz, A. (2007). Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. USA 104: 9451-9456 [Abstract] [Full Text]  
  • Maor, Y., Rahav, G., Belausov, N., Ben-David, D., Smollan, G., Keller, N. (2007). Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus Bacteremia in a Tertiary Care Center. J. Clin. Microbiol. 45: 1511-1514 [Abstract] [Full Text]  
  • Fox, P. M., Climo, M. W., Archer, G. L. (2007). Lack of Relationship between Purine Biosynthesis and Vancomycin Resistance in Staphylococcus aureus: a Cautionary Tale for Microarray Interpretation. Antimicrob. Agents Chemother. 51: 1274-1280 [Abstract] [Full Text]  
  • Renzoni, A., Barras, C., Francois, P., Charbonnier, Y., Huggler, E., Garzoni, C., Kelley, W. L., Majcherczyk, P., Schrenzel, J., Lew, D. P., Vaudaux, P. (2006). Transcriptomic and Functional Analysis of an Autolysis-Deficient, Teicoplanin-Resistant Derivative of Methicillin-Resistant Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 3048-3061 [Abstract] [Full Text]  
  • McCallum, N., Karauzum, H., Getzmann, R., Bischoff, M., Majcherczyk, P., Berger-Bachi, B., Landmann, R. (2006). In Vivo Survival of Teicoplanin-Resistant Staphylococcus aureus and Fitness Cost of Teicoplanin Resistance.. Antimicrob. Agents Chemother. 50: 2352-2360 [Abstract] [Full Text]  
  • Brown, D. F. J., Edwards, D. I., Hawkey, P. M., Morrison, D., Ridgway, G. L., Towner, K. J., Wren, M. W. D., on behalf of the Joint Working Party of the Britis, (2005). Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 56: 1000-1018 [Abstract] [Full Text]  
  • Adem, P. V., Montgomery, C. P., Husain, A. N., Koogler, T. K., Arangelovich, V., Humilier, M., Boyle-Vavra, S., Daum, R. S. (2005). Staphylococcus aureus Sepsis and the Waterhouse-Friderichsen Syndrome in Children. NEJM 353: 1245-1251 [Abstract] [Full Text]  
  • Chambers, H. F. (2005). Evaluation of Ceftobiprole in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 884-888 [Abstract] [Full Text]  
  • Palazzo, I. C. V., Araujo, M. L. C., Darini, A. L. C. (2005). First Report of Vancomycin-Resistant Staphylococci Isolated from Healthy Carriers in Brazil. J. Clin. Microbiol. 43: 179-185 [Abstract] [Full Text]  
  • Sieradzki, K., Tomasz, A. (2003). Alterations of Cell Wall Structure and Metabolism Accompany Reduced Susceptibility to Vancomycin in an Isogenic Series of Clinical Isolates of Staphylococcus aureus. J. Bacteriol. 185: 7103-7110 [Abstract] [Full Text]  
  • Liu, C., Chambers, H. F. (2003). Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods. Antimicrob. Agents Chemother. 47: 3040-3045 [Full Text]  
  • Pavie, J., Lefort, A., Ploy, M.-C., Massias, L., Chau, F., Garry, L., Denis, F., Fantin, B. (2003). Influence of Reduced Susceptibility to Glycopeptides on Activities of Vancomycin and Teicoplanin against Staphylococcus aureus in Experimental Endocarditis. Antimicrob. Agents Chemother. 47: 2018-2021 [Abstract] [Full Text]  
  • Kim, H. B., Park, W. B., Lee, K. D., Choi, Y. J., Park, S. W., Oh, M.-d., Kim, E.-C., Choe, K. W. (2003). Nationwide Surveillance for Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Korea. J. Clin. Microbiol. 41: 2279-2281 [Abstract] [Full Text]  
  • Reipert, A., Ehlert, K., Kast, T., Bierbaum, G. (2003). Morphological and Genetic Differences in Two Isogenic Staphylococcus aureus Strains with Decreased Susceptibilities to Vancomycin. Antimicrob. Agents Chemother. 47: 568-576 [Abstract] [Full Text]  
  • Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., Ferraz, V., Hiramatsu, K. (2003). Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus. J. Clin. Microbiol. 41: 5-14 [Abstract] [Full Text]  
  • Schaaff, F., Reipert, A., Bierbaum, G. (2002). An Elevated Mutation Frequency Favors Development of Vancomycin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 3540-3548 [Abstract] [Full Text]  
  • Denis, O., Nonhoff, C., Byl, B., Knoop, C., Bobin-Dubreux, S., Struelens, M. J. (2002). Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 50: 383-391 [Abstract] [Full Text]  
  • Boyle-Vavra, S., Carey, R. B., Daum, R. S. (2001). Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother 48: 617-625 [Abstract] [Full Text]  
  • Grif, K., Dierich, M. P., Pfaller, K., Miglioli, P. A., Allerberger, F. (2001). In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48: 209-217 [Abstract] [Full Text]  
  • Walsh, T. R., Bolmstrom, A., Qwarnstrom, A., Ho, P., Wootton, M., Howe, R. A., MacGowan, A. P., Diekema, D. (2001). Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. J. Clin. Microbiol. 39: 2439-2444 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Berger-Bachi, B., Lew, D. P. (2001). In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 47: 163-170 [Abstract] [Full Text]  
  • Trakulsomboon, S., Danchaivijitr, S., Rongrungruang, Y., Dhiraputra, C., Susaemgrat, W., Ito, T., Hiramatsu, K. (2001). First Report of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycin in Thailand. J. Clin. Microbiol. 39: 591-595 [Abstract] [Full Text]  
  • Boyle-Vavra, S., Labischinski, H., Ebert, C. C., Ehlert, K., Daum, R. S. (2001). A Spectrum of Changes Occurs in Peptidoglycan Composition of Glycopeptide-Intermediate Clinical Staphylococcus aureus Isolates. Antimicrob. Agents Chemother. 45: 280-287 [Abstract] [Full Text]  
  • Bobin-Dubreux, S., Reverdy, M.-E., Nervi, C., Rougier, M., Bolmström, A., Vandenesch, F., Etienne, J. (2001). Clinical Isolate of Vancomycin-Heterointermediate Staphylococcus aureus Susceptible to Methicillin and In Vitro Selection of a Vancomycin-Resistant Derivative. Antimicrob. Agents Chemother. 45: 349-352 [Abstract] [Full Text]  
  • Boyle-Vavra, S., Hahm, J., Sibener, S. J., Daum, R. S. (2000). Structural and Topological Differences between a Glycopeptide-Intermediate Clinical Strain and Glycopeptide-Susceptible Strains of Staphylococcus aureus Revealed by Atomic Force Microscopy. Antimicrob. Agents Chemother. 44: 3456-3460 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»